Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha
Labeling for reduction of cardiovascular risk may help a bit with payers, but the "twin problem" of pricing and lack of patient adherence is likely to continue to present hurdles for reimbursement.
You may also be interested in...
Established brands Repatha and Otezla, new launches Lumakras and Tezspire, and the Amjevita-led biosimilars portfolio will provide most of the company’s growth through the end of this decade.
Newer products are gaining ground, but not fast enough to replace sales as blockbuster products face competition. Scrip spoke with the company's global commercial head about the strategy going forward.
Although only interim data from six treated patients, Capricor’s Phase II DMD study shows improvements in upper limb performance, grip strength and respiration. Cardiac performance shows positive trend, but not yet statistical significance.